این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Pathology، جلد ۲۰، شماره ۱، صفحات ۸۴-۸۹
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی The In vitro Effect of Nanoliposomal Amphotericin B Against Rhizopus arrhizus Isolated From COVID-19-Associated Mucormycosis Patients
چکیده انگلیسی مقاله Background & Objective: Rhizopus arrhizus, a major contributor to COVID-19-associated mucormycosis (CAM) globally. Nanoliposomal amphotericin B (NLAmB) presents a promising approach due to its enhanced drug delivery and reduced side effects. This study aimed to assess the in vitro antifungal susceptibility of NLAmB against R. arrhizus isolated from CAM patients.
Methods: Thirty-nine R. arrhizus isolated from CAM patients were identified through phenotypic characterization, MALDI-TOF, and the internal transcribed spacer rDNA region (ITS) sequencing approaches. Antifungal susceptibility testing (AFST) for NLAmB, amphotericin B (AmB), posaconazole (PSC), and isavuconazole (ISC) was conducted through broth microdilution methods according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standard E.DEF 9.4. Results were analyzed for MIC ranges, MIC50, MIC90, and distributions.
Results: NLAmB demonstrated superior in vitro efficacy against R. arrhizus (MIC50/90, 0.063/0.25 μg/ml) compared to AmB, PSC, and ISC. PSC exhibited notable activity (MIC range: ≤0.031 - ≥16 μg/ml).
Conclusion: The study emphasized NLAmB's sustained activity, making it a potential alternative to LAmB. Further exploration and clinical correlation are warranted to validate NLAmB in CAM treatment.
کلیدواژه‌های انگلیسی مقاله Nanoparticle Drug Delivery System,Liposome,Amphotericin B,Rhizopus oryzae,COVID-19,Mucormycosis
نویسندگان مقاله Ali Ahmadi |
Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Sayed Jamal Hashemi |
Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Seyed Mahdi Rezayat |
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Roshanak Daei Ghazvini |
Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Mahmoud Reza Jaafari |
Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Jamileh Esmaeili |
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Fatemeh Saiedmohammadi |
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Farzaneh Afshari |
Cancer Immunology Project (CIP), Universal Scientific Education & Research Network (USERN), Tehran, Iran

Laura Alcazar-Fuoli |
Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain

Alireza Abdollahi |
Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Sadegh Khodavaisy |
Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

نشانی اینترنتی https://ijp.iranpath.org/article_721057_ad56a9069777117ffd5802c5b490f996.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات